The Mullings Group’s Post

By equipping healthcare teams with optimized bone marrow biopsy tools, providers like MPM Medical Supply enable safer, more accurate procedures. Efficient biopsies translate into prompt diagnostic insights and enhanced patient satisfaction while also benefiting hospital/clinic productivity. https://lnkd.in/e9WsEa4Q

More data validating the ability of the WATS3D AI platform to help detect precancerous lesions.

🔍 Exciting news! A recent #WATS3D study showcases a high level of accuracy and reproducibility, where pathologists reached near perfect agreement in diagnosis.🔬 Read it here: https://bit.ly/3Pl7I7c   Unlike standard forceps biopsy, which often exhibits low interobserver agreement, 𝐖𝐀𝐓𝐒𝟑𝐃 𝐝𝐞𝐦𝐨𝐧𝐬𝐭𝐫𝐚𝐭𝐞𝐬 𝐬𝐮𝐩𝐞𝐫𝐢𝐨𝐫𝐢𝐭𝐲 𝐨𝐯𝐞𝐫 𝐭𝐡𝐞 𝐜𝐮𝐫𝐫𝐞𝐧𝐭 𝐛𝐢𝐨𝐩𝐬𝐲 𝐩𝐫𝐨𝐭𝐨𝐜𝐨𝐥. 𝐓𝐡𝐢𝐬 𝐩𝐫𝐨𝐯𝐢𝐝𝐞𝐬 𝐩𝐡𝐲𝐬𝐢𝐜𝐢𝐚𝐧𝐬 𝐰𝐢𝐭𝐡 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞𝐝 𝐜𝐨𝐧𝐟𝐢𝐝𝐞𝐧𝐜𝐞 𝐢𝐧 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬, 𝐮𝐥𝐭𝐢𝐦𝐚𝐭𝐞𝐥𝐲 𝐞𝐧𝐡𝐚𝐧𝐜𝐢𝐧𝐠 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐜𝐚𝐫𝐞. Learn more in our press release!   https://lnkd.in/e2PHrB4c #medicalinnovation #patientcare #biopsy

New Breakthrough in Breast Cancer Imaging! Exciting research published in Academic Radiology shows that F-18 FAPI PET/CT is a game-changer in staging newly diagnosed breast cancer, leading to more accurate detection of metastases compared to traditional F-18 FDG PET/CT. A study from China-Japan Union Hospital reveals that F-18 FAPI PET/CT leads to a significant upstaging in 47.4% of cases, far higher than FDG PET/CT (34.2%). This breakthrough could improve treatment decisions, especially for patients with small malignant lesions or low FDG uptake. By offering higher sensitivity, F-18 FAPI PET/CT ensures better detection of regional and distant metastases, helping doctors select the best treatments and improve outcomes for patients. #CancerSurgeryKanyakumari #BreastCancerAwareness #cancerresearch #medicaladvances #F18FAPIPETCT #CancerImaging Dr. Lala Robin MBBS, MS (General Surgery), DrNB (Surgical Oncology) Consultant General / Laparoscopic Surgeon Surgical Oncologist Contact for appointments in Whatsapp @ 094433 36060 https://lnkd.in/gePmPcNB

According to Next Move Strategy Consulting, the global TAVI market size is anticipated to surpass $16.32 billion by 2030 reflecting a CAGR of 14.6% during the forecast period till 2030. The TAVI market is witnessing a paradigm shift in cardiac interventions as innovative technologies and minimally invasive procedures gain prominence. Technological advancements, like the development of new-generation TAVI devices with lower infection risks, are poised to propel the market forward. This is because these innovations will not only improve patient outcomes but also expand the pool of eligible candidates for the procedure. The TAVI market comprises key players such as Abbott, JC Medical, Inc., Boston Scientific , JenaValve Technology, Inc., Edwards Lifesciences, Medtronic, Venus Medtech Europe among others. #tavimarket #healthcare #medicalequipments #lifescience #marketresearch #globaltrends #businessinsights

No convergence of Kaplan-Meier rates over time between Evolut™ #TAVR and #SAVR in low-risk patients out to 4 years. Discover the excellent clinical outcomes from the Evolut Low Risk mid-term results. https://bit.ly/3RIf5Yg Risk info: https://bit.ly/47U217z

💰 Johnson & Johnson to acquire Shockwave Medical in $13.1bn deal Shockwave Medical has developed the Intravascular Lithotripsy (IVL) technology. IVL is designed to be a minimally invasive, catheter-based treatment for calcified arterial lesions, these lesions, capable of reducing blood flow and inducing pain or heart attacks, pose a significant risk. Shockwave Medical’s technology is intended to transform the treatment of atherosclerotic cardiovascular disease by utilising safe sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly enhanced patient outcomes. Johnson & Johnson chairman and CEO Joaquin Duato said: “With our focus on Innovative Medicine and MedTech, Johnson & Johnson has a long history of tackling cardiovascular disease – the leading cause of death globally. “The acquisition of Shockwave and its leading IVL technology provides a unique opportunity to accelerate our impact in cardiovascular intervention and drive greater value for patients, shareholders and health systems.” Upon finalisation of the transaction, Shockwave Medical will function as a distinct business unit under Johnson & Johnson MedTech. Its financials will be incorporated into Johnson & Johnson MedTech’s cardiovascular portfolio, formerly known as Interventional Solutions. Shockwave Medical president and CEO Doug Godshall said: “As part of a larger, more diverse organisation, with broad expertise and a core focus on improving patient outcomes, we are confident we will be able to further solidify IVL as the global standard of care for patients.” Read more online: https://lnkd.in/esB2z37K 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #johnsonandjohnson #shockwavemedical

Promising results - two years into a study of the Aspirex Mechanical Aspiration Thrombectomy catheter, clinicians around Europe are seeing high efficacy rates in their patients. Dr Michael Lichtenberg, MD, of the Arnsberg Vascular Clinic in Arnsberg, Germany, presented early findings at the recent Leipzig Interventional Course. "I was asked to organize this trial to analyze the safety and efficacy of this catheter to remove thrombus from patients with iliofemoral deep vein thrombosis," he said, noting that after 24 months, the primary efficacy endpoint was 97.5%. “To remove thrombus and restore blood flow is the very definition of procedural success. This shows the efficacy of such a device, and this is super important.” Learn more: https://okt.to/YbT3FA #Cardiovascular #DVT #catheter #research #HealthcareMadePractical

Discovering you have competition (with your same original idea) is awesome... The recent news of V-Wave's acquisition by J&J is a triumphant win for medtech, patients, and the whole ecosystem. There is a ton of signaling that comes with this on J&J really getting back into the Cardiovascular world as well highlighting the strong M&A potential of medtech solutions specially given the dearth of IPOs recently. But it also beckons a great lesson about resiliency for early stage startups. Back in 2016 during the early part of the Biodesign process, I had recently discovered this unmet pressure overload clinical need that V-wave addresses at a small conference in San Antonio and had brought it back to the team. Based on some ancient studies and our intuition about using "the pathology of another condition to treat another", we had convinced ourselves that this interatrial shunting approach would work. Our initial idea that we got super excited about was this fancy nitinol stent with a valve mechanism that you could introduce with a catheter system. We knew this meant a long Class 3 PMA process, but we were ready for it. Then almost 24 hours later, we discovered Corvia Medical, Inc. and V-Wave ...who had that same idea almost 5 year earlier...had already raised 10s of millions of dollars... an already completed early human studies. We were bummed for like 24 hours. But then over the weekend I realized something.... This is awesome. We were right. The idea was good. And somebody had already put in a ton of time and effort to prove we were right. We could have just called it then and there, but we didn't give up. As this new bit of adversity sparked a new level of creativity. As we could now think through the problem given the new data and context that our competitors brought to the problem. It allowed us to come up with arguably one of my coolest and craziest ideas of my career that would go on to become the Alleviant Medical device (which IMHO is a better approach, but only time will tell 😆 ). So if you are early on in your startup's journey, don't see competition as a bad thing. Because now you have a more tangible flag post to make something 10x better that people want.

#SFNR2024 #INReporters 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝗰𝗮𝗹 𝗧𝗵𝗿𝗼𝗺𝗯𝗲𝗰𝘁𝗼𝗺𝘆 𝗢𝗿𝗮𝗹 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 👉 Dr. Nicolaos from Rothschild foundation described the impact of the recent aspiration catheters reimbursement arrest by the french authority. He reported a significant reduction of the use of aspiration catheters by physicians & a 1000€ increase of cost per procedure for the institution. He then discussed solutions to limit the impact of this regulation on our practice, insisting on the need to 𝙥𝙧𝙤𝙫𝙞𝙙𝙚 𝙩𝙝𝙚 𝙗𝙚𝙨𝙩 𝙩𝙤𝙤𝙡𝙨 𝙛𝙤𝙧 𝙥𝙝𝙮𝙨𝙞𝙘𝙞𝙖𝙣𝙨 𝙩𝙤 𝙩𝙧𝙚𝙖𝙩 𝙩𝙝𝙚𝙞𝙧 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨. 👉 Dr. Bourcier presented the 𝙑𝙀𝘾𝙏𝙊𝙍 𝙨𝙩𝙪𝙙𝙮 which was conducted through the Jeunes En Neuroradiologie Interventionnelle JENI research network. For SVS+ occlusion there was no superiority of first-line combined vs contact aspiration in eTICI 2c/3 final result, but 𝙝𝙞𝙜𝙝𝙚𝙧 𝙛𝙞𝙧𝙨𝙩 𝙥𝙖𝙨𝙨 𝙚𝙏𝙄𝘾𝙄 2𝙗/3 𝙞𝙣 𝙛𝙖𝙫𝙤𝙧 𝙤𝙛 𝙘𝙤𝙢𝙗𝙞𝙣𝙚𝙙 𝙨𝙩𝙧𝙖𝙩𝙚𝙜𝙮. 👉 Dr. Pop presented the results of the Catchview stent retriever (SR) evaluation in a 171 patients’ series. When matched with 617 patients treated with other SR in the ETIS registry, authors d𝙚𝙢𝙤𝙣𝙨𝙩𝙧𝙖𝙩𝙚𝙙 𝙩𝙝𝙚 𝙣𝙤𝙣-𝙞𝙣𝙛𝙚𝙧𝙞𝙤𝙧𝙞𝙩𝙮 𝙤𝙛 𝘾𝘼𝙏𝘾𝙃𝙑𝙄𝙀𝙒 𝙘𝙤𝙢𝙥𝙖𝙧𝙚𝙙 𝙬𝙞𝙩𝙝 𝙎𝙩𝙖𝙣𝙙𝙖𝙧𝙙 𝙎𝙍. Interestingly, the Catchview achieved : ➡️ higher reperfusion rates at the end of endovascular therapy ➡️ higher rates of favorable outcomes at 90 days 📝 https://lnkd.in/e5wK5XYv He then insisted on the versatility of the Catchview SR family with 6, 4 & 3mm sizes, allowing notably a 𝙨𝙖𝙛𝙚 𝙖𝙘𝙘𝙚𝙨𝙨 𝙩𝙤 𝙙𝙞𝙨𝙩𝙖𝙡 𝙤𝙘𝙘𝙡𝙪𝙨𝙞𝙤𝙣𝙨 𝙬𝙞𝙩𝙝 𝙩𝙝𝙚 𝘾𝙖𝙩𝙘𝙝𝙫𝙞𝙚𝙬 𝙢𝙞𝙣𝙞 𝙎𝙍. 👉 Dr. Abousleiman from Toulouse ended the session with a study aiming at comparing angioplasty vs stenting for acute carotid dissections. He reported a 66% rate of internal carotid permeability at day 1 for angioplasty vs 76% for stenting. 💡 𝐒𝐭𝐚𝐲 𝐭𝐮𝐧𝐞𝐝 Dr. Jildaz CAROFF Content dedicated for an international audience